Immunotherapy for Glioma Promises and Challenges

被引:29
作者
Han, Seunggu J. [1 ]
Zygourakis, Corinna [1 ]
Lim, Michael [2 ]
Parsa, Andrew T. [1 ,3 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[2] Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Neurosurg, Baltimore, MD 21287 USA
[3] Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
关键词
Glioma; Glioblastoma multiforme; Brain tumors; Central nervous system; Immunotherapy; Cytokines; B cells; T cells; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; 81C6; CENTRAL-NERVOUS-SYSTEM; CONVECTION-ENHANCED DELIVERY; CYTOTOXIC T-CELLS; RECURRENT MALIGNANT GLIOMAS; ACTIVATED KILLER-CELLS; IL4-PSEUDOMONAS EXOTOXIN NBI-3001; TUMOR-INFILTRATING LYMPHOCYTES; INTERLEUKIN-4; IL-4; RECEPTORS;
D O I
10.1016/j.nec.2012.05.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Novel immunotherapeutic modalities are being pursed in the treatment of high-grade gliomas. This article explains how tumors suppress immune function in the brain. It specifically describes the ways in which tumors limit effective communication with immune cells, secrete immune-inhibitory cytokines and molecules, and express molecules that induce apoptosis of immune cells. It also defines 3 different immunotherapeutic approaches to counteract this tumor-associated immunosuppression: cytokine therapy, passive immunotherapy (either serotherapy or adoptive immunotherapy), and active immunotherapy. Although immunotherapeutic approaches have met with mixed success so far, immunotherapy continues to be actively pursued because of its potential to attack infiltrating high-grade gliomas.
引用
收藏
页码:357 / +
页数:15
相关论文
共 191 条
[1]   Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy [J].
Akabani, G ;
Cokgor, I ;
Coleman, RE ;
Trotter, DG ;
Wong, TZ ;
Friedman, HS ;
Friedman, AH ;
Garcia-Turner, A ;
Herndon, JE ;
DeLong, D ;
McLendon, RE ;
Zhao, XG ;
Pegram, CN ;
Provenzale, JM ;
Bigner, DD ;
Zalutsky, MR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (04) :947-958
[2]  
Akabani G, 2005, J NUCL MED, V46, P1042
[3]  
Aloisi F, 1999, EUR J IMMUNOL, V29, P2705, DOI 10.1002/(SICI)1521-4141(199909)29:09<2705::AID-IMMU2705>3.0.CO
[4]  
2-1
[5]  
Aloisi F, 1998, J IMMUNOL, V160, P4671
[6]   Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study [J].
Badie, B ;
Schartner, JM ;
Paul, J ;
Bartley, BA ;
Vorpahl, J ;
Preston, JK .
JOURNAL OF NEUROSURGERY, 2000, 93 (04) :634-639
[7]   Expression of Fas ligand by microglia: possible role in glioma immune evasion [J].
Badie, B ;
Schartner, J ;
Prabakaran, S ;
Paul, J ;
Vorpahl, J .
JOURNAL OF NEUROIMMUNOLOGY, 2001, 120 (1-2) :19-24
[8]   INTRATUMORAL LAK CELL AND INTERLEUKIN-2 THERAPY OF HUMAN GLIOMAS [J].
BARBA, D ;
SARIS, SC ;
HOLDER, C ;
ROSENBERG, SA ;
OLDFIELD, EH .
JOURNAL OF NEUROSURGERY, 1989, 70 (02) :175-182
[9]   Pharmacologic immunosuppression [J].
Barshes, NR ;
Goodpastor, SE ;
Goss, JA .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 :411-420
[10]   Gene therapy of experimental brain tumors using neural progenitor cells [J].
Benedetti, S ;
Pirola, B ;
Pollo, B ;
Magrassi, L ;
Bruzzone, MG ;
Rigamonti, D ;
Galli, R ;
Selleri, S ;
Di Meco, F ;
De Fraja, C ;
Vescovi, A ;
Cattaneo, E ;
Finocchiaro, G .
NATURE MEDICINE, 2000, 6 (04) :447-450